Aptevo Therapeutics Inc. (APVO) Financials
APVO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 19.9 million | 8.3 million |
| Dec. 31, 2025 | 27.2 million | 9.8 million |
| Sept. 30, 2025 | 27.0 million | 9.6 million |
| June 30, 2025 | 15.6 million | 9.1 million |
APVO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -8.0 million | 57000 |
| Dec. 31, 2025 | -5.2 million | 2000 |
| Sept. 30, 2025 | -6.7 million | 77000 |
| June 30, 2025 | -7.1 million | -163000 |
APVO Net Income
No data available :(
APVO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 14.5 million | 3.5 million | - |
| Dec. 31, 2025 | 21.6 million | - | 3.8 million |
| Sept. 30, 2025 | 21.1 million | - | 4.0 million |
| June 30, 2025 | 9.4 million | - | 4.2 million |
APVO Shares Outstanding
APVO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 3.9 million | 2.9 million | - |
| Dec. 31, 2025 | - | 3.5 million | 2.5 million | - |
| Sept. 30, 2025 | - | 4.0 million | 3.6 million | - |
| June 30, 2025 | - | 3.3 million | 2.9 million | - |
APVO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 35000 |
| Dec. 31, 2025 | -220000 | 81000 |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | 49000 |
APVO Revenue by Segment
Graph available only for paid members. Upgrade to see it.
APVO
Price: $4.72
52 week price:
Earnings Per Share: -87.27 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 73389
Ebitda: -9.5 millionMarket Capitalization: 5.5 million